Investor Newsletter

Issue 05 2019

MicroPort®

MicroPort® Receives Reimbursement in France for Firehawk®

May 24, 2019 - MicroPort Scientific Corporation ("MicroPort®", HK:0853) announced today that Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") has obtained reimbursement in France. This decision by the French Economic Committee for Health Products (CEPS) was published in the French Journal Officiel (JO) today.

This positive outcome is based on the convincing clinical data from the Firehawk® TARGET All-Comers (TARGET AC) trial, a prospective, multi-center, randomized controlled clinical trial consisting of entirely European-based patients with ischemic coronary artery disease. In September 2018, the 12-month results of the Firehawk® TARGET AC trial were published in the world leading medical journal the Lancet. This is the first time that clinical data from a China manufactured drug eluting stent has been published in the Lancet since its first publication nearly 200 years ago. In May 2019, MicroPort® announced 24-month follow-up results at EuroPCR 2019, which will be supported by a concomitant publication in the Journal of the American College of Cardiology (JACC).

Firehawk® received the CE Mark in 2015. This reimbursement allows MicroPort® to widen its access to one of the most important European market for coronary stents. MicroPort® will continue with its commitment to release more high-quality, innovative and high-end medical devices to France, to provide the French patients with more comprehensive therapeutic solutions.

MicroPort



MicroPort® Announces Successful Non-Inferior Two-Year Clinical Data for its Firehawk Drug-eluting Stent at EuroPCR 2019

On May 22, 2019, MicroPort® released the data at 24 months from its TARGET All-Comers (TARGET AC) trial. Similar to one-year primary endpoint data which has been published in The Lancet, the 24 months results of the TARGET AC trial demonstrated that vessels treated with Firehawk® showed non-inferiority results when compared to vessels treated with the Xience family of drug-eluting stents. These newest clinical data were presented at EuroPCR 2019 conference held in Paris by Dr. Bo Xu, a Steering Committee member of TARGET AC trial and Director at Fu Wai Hospital, Beijing, China. This presentation will be supported by a concomitant publication in the Journal of the American College of Cardiology (JACC).

"The two-year follow-up of the TARGET All Comers study shows similar safety and efficacy profiles of the Firehawk® and Xience stents," said Dr. Bo Xu during his EuroPCR 2019 presentation concluding remarks, "The incidence of target lesion failure (TLF) beyond one year was low and comparable for both treatment arms, with a low rate of stent thrombosis in a broad all-comers population."

MicroPort



MicroPort® Held Firehawk® Stent Symposium during EuroPCR 2019

The EuroPCR 2019 was held at the Palais des Congrès in Paris, France, from May 21 to 24. MicroPort sponsored the "Latest Clinical and Technology Update of Firehawk Target Eluting Stent Platform" symposium during EuroPCR 2019 and attracted extensive attention.

The symposium was co-chaired by Prof. Martin B. Leon from Center for Interventional Vascular Therapy (CIVT) at Columbia University Medical Center and Prof. William Wijns from National University of Ireland Galway, who is Co-Director of EuroPCR. Firstly, Prof. Alexandra Lansky from Yale University School of Medicine spoke of the 24-month follow-up results of the Firehawk® Rapamycin Target Eluting Stent System ("Firehawk®") TARGET All-Comer ("TARGET AC") study. The target lesion failure (TLF) rate of Firehawk® stent is 8.7% at 24 months, which further showed non-inferiority of the Firehawk® stent featuring innovative target eluting technology and the internationally recognized Xience stent possessing the richest clinical data, with the potential safety of Firehawk® stent higher than that of Xience stent. With regards to myocardial infarction (MI) related to the target vessel and ischemia-driven target lesion revascularization, the 24-month follow-up results of Firehawk® stent demonstrated advantages over its control arm. Both Mr. Andreas Baumbach from Bristol Heart Institute and Director Bo Xu from Chinese Academy of Medical Sciences Fuwai Hospital said they were expecting the long-term follow-up results from the TARGET AC study.

MicroPort

Tubridge® Holds Fifth Presentation at World Live Neurovascular Conference (WLNC)

The World Live Neurovascular Conference (WLNC) was held here on May 1, 2019, bringing together the world's top neurovascular internationalists to conduct exchanges and share expertise. The globally influential scientific conference in the field of interventional neurology aimed to showcase the latest progress of clinical researches in the field with the techniques at the forefront of development. The Tubridge® Vascular Reconstruction Device ("Tubridge®") of MicroPort NeuroTech (Shanghai) Co., Ltd. ("MicroPort® NeuroTech"), which is a blood flow diverting device, held its fifth presentation during the Live Case session of WLNC since 2014.

Tubridge® is an innovative result of MicroPort® NeuroTech's 12-year independent R&D to treat intracranial large and huge aneurysms. It obtained the registration approval from National Medical Products Administration of China (NMPA) in March 2018 as the only Chinese-made blood flow diverting device produced in China. From 2014 on, WLNC witnessed the R&D, launch and clinical applications of Tubridge® along with the endorsements it received from global neurovascular interventionalists. As a leading innovation-driven high-end medical device maker from China, MicroPort® NeuroTech will continue to help rev up the development of China's high-end medical devices within the interventional neurology landscape and provide more comprehensive cerebrovascular interventional solutions.

MicroPort

MicroPort® EP Teams up with MicroPort® CRM to Attend Annual Meeting of the German Society of Cardiology (DGK)

The 85th edition of the Annual Meeting of the German Society of Cardiology (DGK), which is the biggest national congress in cardiology in Europe and boasts a long history and grand reputation within its sector, was held recently in Mannheim, Germany. Focused on cutting-edge diagnostic and treatment technologies for cardiac diseases, the DGK brought together many KOLs in this field to discuss innovation in cardiac interventional medical devices and the relevant procedures and provided a platform of scientific exchanges for global physicians. The DGK attracted more than 8,900 cardiologists and physicians. The products of MicroPort® EP and MicroPort® CRM were jointly presented for the first time at the DGK.

During the DGK, MicroPort® EP and MicroPort® CRM showcased at their joint booth a series of innovative products including Columbus® 3D EP Navigation System ("Columbus®"), FireMagic™ 3D Irrigated Ablation Catheter, FireMagic™ Cardiac RF Ablation Catheter, EasyFinder™ Steerable Curve Diagnostic Catheter, Platinium Implantable Cardioverter Defibrillator (ICD), Rega® Family Implantable Pacemakers, 3 Tesla MRI conditional pacemaker portfolio and Smart Touch™ tablet programmer.

MicroPort

MicroPort® Attends the 22nd Edition of China Cardiovascular Intervention Forum (CCIF 2019)

The 22nd Edition of China Cardiovascular Intervention Forum (CCIF 2019) was held here, bringing together many cardiologists from both China and abroad to discuss the new development, new results and new experience in the cardiovascular field. MicroPort® took part in CCIF 2019 and sponsored a case competition named List of Langya.

The case competition took place with the theme of "Challenging Diseases, Complex Lesions" during CCIF 2019, with 12 outstanding cases selected from across China. The cases were reviewed by a panel comprising renowned Chinese physicians including Prof. Jinghua Liu from Beijing Anzhen Hospital of Capital Medical University, Prof. Yan Li from Xijing Hospital of Air Force Medical University, Prof. Lixia Yang from Chinese PLA 902 Hospital, and Prof. Yanqing Wu from the Second Affiliated Hospital of Nanchang University. Prof. Jun Liu from Xiangya Hospital, Central South University and Prof. Qing He from Shanghai Ninth People's Hospital ended up winning the top prize. Throughout the case competition, the physicians had continual and heated discussions and exchanges on their clinical experience in the handling of challenging diseases.



MicroPort® has been sponsoring the case competition since 2016 and received favorable comments at several well-known domestic symposiums. The case competition at CCIF2019 marked the fourth to be held during the event to fully demonstrate the outstanding clinical performance of the MicroPort® coronary artery stent products with top physicians' discussions on specific topics and perspectives. Prof. Yan Li from Xijing Hospital of Air Force Medical University commented that the case competition had established itself as a brand campaign of MicroPort®, as every edition of it had provided highly valuable expertise for the physicians to learn, making the case completion, the physicians had continual and heated discussions and exchanges on their clinical experience in the handling of challenging diseases.

MicroPort® Displays Product Portfolios at the 12th Annual Conference of Chinese Association of Orthopaedic Surgeons (CAOS 2019)

The 12th Annual Conference of Chinese Association of Orthopaedic Surgeons (CAOS 2019) was held in Beijing, China, on May 23, featuring scientific exchanges on more than 10 disciplines including joints, spine, trauma, and sports medicine. The international high-level continuing education courses were provided during the CAOS 2019 with the cooperation with the renowned scientific organizations such as AAOS, ASIA, NASS, HSS and ICJR, to have every doctor benefit from continuing education in orthopedics and help the attending doctors build up on professional expertise. MicroPort® exhibited innovative products in the disciplines of knee, hip, and spine and trauma at CAOS 2019.

Shanghai MicroPort Orthopedics MedTech Co., Ltd. ("MicroPort® Orthopedics") presented in details the product features and technical advantages of Evolution® Medial-Pivot Total Knee Replacement System ("Evolution®") and Supercapsular Percutaneously Assisted Total Hip Arthroplasty ("SuperPath®") to the healthcare professionals through product displays, live cases and instrument demonstrations.

Suzhou MicroPort Joint MedTech Co., Ltd. ("MicroPort® Joint") presented the SoSuperior™ and Aspiration™ Medial-Stabilized Total Knee Replacement Systems, which attracted extensive attention from the healthcare professionals in attendance. As the first Chinese-made Medial-Stabilized Total Knee Replacement Systems winning marketing approvals in China and boasting independent intellectual property, the design rationale of the two products stems from the unique Medial-Pivot Knee of MicroPort® Orthopedics.

MicroPort® NeuroTech Attends the 16th Edition of China Forum of Cerebrovascular Diseases (CFCVD)

The 16th Edition of China Forum of Cerebrovascular Diseases (CFCVD), which is one of the most influential scientific events in the field of cerebrovascular disease therapies in China, was held in Beijing, China recently, following the academic rationale of linking basic anatomy and latest therapies of interest to cover the topics including cerebral revascularization, acute stroke treatment, unruptured aneurysm and hemorrhage. CFCVD brought together over 1,000 Chinese and foreign healthcare professionals and researchers. MicroPort® NeuroTech presented Tubridge® and WILLIS® Intracranial Stent Graft System ("WILLIS®") at CFCVD.

Tubridge® is an innovative result of MicroPort® NeuroTech's 12-year independent R&D to treat intracranial large and huge aneurysms. It obtained the registration approval from National Medical Products Administration of China (NMPA) in March 2018 as the first Chinese-made blood flow diverting device produced in China. WILLIS® is the first approved stent graft product to treat intracranial aneurysms in China. It is also independently developed by MicroPort® NeuroTech. As a leading innovation-driven high-end medical device company in China, MicroPort® NeuroTech will keep innovating to provide more comprehensive cerebrovascular interventional solutions for patients and doctors.



MicroPort® Participates in China Brand Day

The third China Brand Day fell on May 10, with its key component, the second edition of the Exposition on China Indigenous Brand ("the Exposition"), being held at Shanghai Exhibition Center from May 10 to 12. As a leading provider of high-end innovative therapeutic solutions in China, MicroPort® intensively participated in a series of activities during the China Brand Day in various forms and attended the Exposition to present Firehawk®, SoSuperior™ Medial-Stabilized Total Knee Replacement System ("SoSuperior™") and Rega® Family Implantable Pacemakers ("Rega®"), which attracted huge attention.

During the recent years, Shanghai has been building up its strategic advantages to promote the Four Brands, namely Shanghai Service, Shanghai Manufacturing, Shanghai Shopping and Shanghai Culture in the its efforts to create a city of global excellence. In 2018, a total of 53 companies obtained the first batch of Shanghai Brand certificates, which included 50 products and 36 items of service. MicroPort® became the only company in the healthcare sector to receive the certificate for Firehawk®. With a strong focus on independent innovation since its foundation dating to over 20 years ago, MicroPort® has released about 300 products to the market. The products have entered nearly 10,000 hospitals globally, covering Asia Pacific, Europe, and the Americas. Every 8 seconds a patient is being implanted with a MicroPort® manufactured device to save a life, improve the quality of a life, or create a new life. The participation of MicroPort® in a series of activities of China Brand Day fully reflected the continuing recognition MicroPort® obtained from the public. In the future, MicroPort® will continue to adhere to its brand ideology of "the Patient Always Comes First". MicroPort® integrates the pursuit of details and the perseverance in innovation into its corporate gene, as well as takes a people-centric approach, to provide the global patients with innovative medical solutions that can prolong and transform lives amid Shanghai's drive for global excellence.



Investor Newsletter

Issue 05 2019

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com